Like other, similar drugs before it, ODM-201 — now properly known by the generic name darolutamide — has apparently hit the primary goal of metastasis-free survival in the Phase III ARAMIS trial, as announced yesterday by Bayer and Orion. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: castration-resistant, darolutamide, hormone-sensitive, metastatic, non-metastatic, ODM-201 | 4 Comments »
We note that Pfizer and Astellas have recently modified the protocols for two large, international, randomized, Phase III clinical trials to see if they can get earlier results that might affect the potential for use of enzalutamide (Xtandi) in some groups of men with hormone-sensitive prostate cancer (HSPC). … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", ARCHES, EMBARK, enzalutamide, hormone-sensitive, metastatic, trial | 6 Comments »
A new paper in the Annals of Oncology has addressed the critical question regarding what might be “the best” way we currently have to start treatment for a man newly diagnosed with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: first line, hormone-sensitive, metastatic, Treatment | 8 Comments »
New guidelines on the management of metastatic, hormone-sensitive prostate cancer have just been released by the American Society for Clinical Oncology (ASCO), based primarily on data from the CHAARTED, STAMPEDE, and LATITUDE trial data. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: guideline, hormone-sensitive, metastatic, Treatment | 2 Comments »
Late yesterday the US Food and Drug Administration announced the approval of abiraterone acetate (Zytiga) + prednisone for the treatment of men with “high-risk, castration-sensitive”, metastatic prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-sensitive, hormone-sensitive, Zytiga | Leave a comment »
At the time of the original presentation of data from the CHAARTED trial, the median follow-up for patients enrolled in this trial was 28.9 months. We now have data from the same 790 patients followed for a median of 53.7 months. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: CHAARTED, follow-up. long-term, hormone-sensitive, metastatic | 10 Comments »
For many years now, people have asked whether specific PSA levels after initiation of androgen deprivation therapy (ADT, also known as “hormone therapy”) have significant predictive impact on long-term survival. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, CHAARTED, deprivation, hormone-sensitive, metastatic, PSA, survival | 5 Comments »
If you are on or thinking about active surveillance (AS) as a way to manage your low-risk prostate cancer, you may want to join Prostate Cancer International’s Active Surveillance Virtual Support Group.
Our most recent CureTalk on Prostate Cancer (on February 21 this year) features Eli Van Allen, MD, of the Broad Institute and the Dana-Farber Cancer Center, talking about the new “Metastatic Prostate Cancer Project” and how you can become part of the solution.
For access to the full list of CureTalks on Prostate Cancer, please click here.
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
